Synonyms: AR67 | compound 14 [PMID:11052802] | DB-67 | DB67 | silatecan
Compound class:
Synthetic organic
Comment: AR-67 is a synthetic, highly lipophilic derivative of the natural alkaloid camptothecin (PubChem CID 24360), with potential antineoplastic [3,5] and radiosensitizing activities [4]. The compound has improved physicochemical properties compared to other camptothecin-derived drugs (e.g. SN-38, the active metabolite of the anti-cancer drug irinotecan, and topotecan) [2].
|
|
References |
1. Arnold SM, Rinehart JJ, Tsakalozou E, Eckardt JR, Fields SZ, Shelton BJ, DeSimone PA, Kee BK, Moscow JA, Leggas M. (2010)
A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies. Clin Cancer Res, 16 (2): 673-80. [PMID:20068096] |
2. Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson Strode J, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL et al.. (2000)
The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem, 43 (21): 3970-80. [PMID:11052802] |
3. Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S, Howe JN, Bingcang A, Latus LJ, Burke TG. (2001)
The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release, 74 (1-3): 325-33. [PMID:11489514] |
4. Chen AY, Shih SJ, Garriques LN, Rothenberg ML, Hsiao M, Curran DP. (2005)
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Mol Cancer Ther, 4 (2): 317-24. [PMID:15713902] |
5. Yeh TK, Li CM, Chen CP, Chuu JJ, Huang CL, Wang HS, Shen CC, Lee TY, Chang CY, Chang CM et al.. (2010)
Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. Pharmacol Res, 61 (2): 108-15. [PMID:19643180] |